Scleroderma and Lupus Health Study Claims No Environmental Link To Disease PDF Print E-mail
Friday, 08 January 2010 22:09
taken from http://www.flickr.com/photos/h_de_c/3291978657/ via creative commonsThe Massachusetts Department of Public Health (DPH) has released the results of an investigation into the occurrence of scleroderma and lupus, two rare chronic diseases, in South Boston. The investigation found that the prevalence of scleroderma was indeed statistically significantly higher than expected among Caucasian females. No specific associations with environmental exposures were identified.

The study did confirm that a previous diagnosis of rheumatoid arthritis was associated with scleroderma and lupus among current and former South Boston residents. Further, the study also found that a family history of specific rheumatic diseases was significantly associated with a diagnosis of scleroderma and lupus.

The Department of Public Health's study was initiated in 1998, as a result of concerns raised by the South Boston community and then-State Senator Stephen F. Lynch, who now represents Massachusetts' 9th congressional district. At that time, the community expressed concerns about a perceived increase in the number of women who had grown up in South Boston and were later diagnosed with scleroderma. Community members also expressed concern about possible environmental exposure.

"The release of this study represents more than ten years of collaboration between the Massachusetts Department of Public Health and the South Boston community to address concerns of the prevalence of scleroderma and lupus," Congressman Stephen F. Lynch said. "I am pleased to see that this study has been completed and the results will guide future research and help those living with these chronic diseases."

DPH Commissioner John Auerbach added, "These types of studies are important and enhance our collaboration with community partners to improve public health."

DPH responded to the communities’ concerns by collaborating with clinical researchers and epidemiologists at Boston Medical Center, Tufts Medical Center and the South Boston Community Health Center to conduct a retrospective case-control study to investigate the occurrences of both diseases and to identify possible contributing factors (environmental and non-environmental) among individuals with scleroderma and lupus. In addition, DPH established a South Boston Community Advisory Committee to facilitate community outreach and ongoing communication.

Study participants were interviewed about their residential, occupational, medical, family and reproductive histories, as well as hobbies and recreational activities in the area. The study also investigated possible historical exposures to a number of sources of environmental pollution, as well as spatial and temporal (time) patterns among current and former residents with these diseases.

Source: Office of Health and Human Services (EOHHS)

If you're logged in, you can download a copy of the report, presentation, and questions and answers below.

 
More articles :

» Why Your Kids Need Vitamin D

Have you checked with your doctor whether your child is getting enough vitamin D needed for his or her growth? According to CDC, only 5% to 13% of breastfed babies and 20% to 37% of formula-fed infants are getting as much vitamin D as the newly...

» HSCT Benefits In Early Diffuse Cutaneous Systemic Sclerosis

Initial results from an international, investigator-initiated, open label phase 3 trial, presented at EULAR 2012, indicate that haematopoietic stem cell transplantation (HSCT) results in better long-term survival than conventional treatment for...

» Vitamins for Scleroderma

is a class of diseases in which your skin and organs tighten and harden. This autoimmune condition occurs when your body produces an excess of , a protein that comprises your connective tissues. Scleroderma may affect the skin on your hands and...

» Actelion Announces FDA Approval of Brand Name, Veletri, for Pulmonary Arterial Hypertension

US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for...

» Cancer Drug Shows Promise For Treating Scleroderma

A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with , according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold...

» Unite Against Scleroderma 2012

For our second year running, the Scleroderma Care Foundation will be hosting its “Unite Against Scleroderma” Awareness Walk around the , Port of Spain. Scheduled to start from 3:00pm, the Walk would be held on Sunday May 6th 2012 and cover one...